Mark S. Blumenkranz, Director at Avalanche Biotechnologies, Inc. (AAVL), sold 26,000 shares at $39.06 ($1.0M) on 2015-04-07, disclosed to the SEC on 2015-04-08.
Scheduled sale ($1.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.59 | 968 | $37K | 3.7% |
| 2 | $38.59 | 21,774 | $840K | 83.4% |
| 3 | $39.06 | 32 | $1K | 0.1% |
| 4 | $39.06 | 726 | $28K | 2.8% |
| 5 | $39.94 | 2,500 | $100K | 9.9% |
| Total | $38.73 avg | 26,000 |
| $1.0M |
| 100% |
| Filing → |
| [AAVL] | SELL | 2015-06-08 | $200K | — | Filing → |
| AAVL | SELL | 2015-05-21 | $37K | — | Filing → |
| [AAVL] | SELL | 2015-05-18 | $798K | — | Filing → |